Fig. 2: Common resistance variants observed in the context of targeted therapy with BTK inhibitors or BCL2 inhibitors. | Leukemia

Fig. 2: Common resistance variants observed in the context of targeted therapy with BTK inhibitors or BCL2 inhibitors.

From: Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice

Fig. 2

Figure 2a depicts variants observed in BTK, Fig. 2b in PLCG2, and Fig. 2c in BCL2. Variants are indicated by blue (missense) or gray (in-frame changes) lollipops positioned on a linear schematic of the protein sequence with domains annotated. Figure created by ProteinPaint (Zhou et al., Nat Genet 2016; PMID: 26711108).

Back to article page